212 related articles for article (PubMed ID: 19702029)
1. [Ribavirin].
Taéron C
Rev Infirm; 2009; (152):47-9. PubMed ID: 19702029
[No Abstract] [Full Text] [Related]
2. Ribavirin in chronic hepatitis C: past and future.
Loustaud-Ratti V; Rousseau A; Marquet P; Denis F; Alain S
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):249-53. PubMed ID: 19344238
[No Abstract] [Full Text] [Related]
3. Assessing ribavirin exposure during pregnancy: the Ribavirin Pregnancy Registry.
Roberts SS
Gastroenterol Nurs; 2008; 31(6):413-7. PubMed ID: 19077835
[TBL] [Abstract][Full Text] [Related]
4. Concurrent antiphospholipid syndrome and cutaneous [corrected] sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C.
Shinohara MM; Davis C; Olerud J
J Drugs Dermatol; 2009 Sep; 8(9):870-2. PubMed ID: 19746680
[TBL] [Abstract][Full Text] [Related]
5. Growth factors during HCV therapy may be "cost-effective", but are they "effective"?
Muir AJ; McHutchison JG
Hepatology; 2006 Dec; 44(6):1400-3. PubMed ID: 17133467
[No Abstract] [Full Text] [Related]
6. Depression in chronic hepatitis: the virus, the drug, or the ethnic background?
Ferenci P; Staufer K
Liver Int; 2008 Apr; 28(4):429-31. PubMed ID: 18339069
[No Abstract] [Full Text] [Related]
7. The role of nursing in managing treatment-associated adverse effects in patients with hepatitis C.
Leone NE
Gastroenterol Nurs; 2002; 25(5):201-3. PubMed ID: 12394396
[TBL] [Abstract][Full Text] [Related]
8. [The importance of using ribavirin in treating chronic hepatitis C].
Xie Y; Li MH
Zhonghua Gan Zang Bing Za Zhi; 2006 Dec; 14(12):930-1. PubMed ID: 17196140
[No Abstract] [Full Text] [Related]
9. Hepatitis C--who should be treated?
Wolfe GS
Lippincotts Case Manag; 2005; 10(4):213-6. PubMed ID: 16056118
[No Abstract] [Full Text] [Related]
10. Hepatitis C: current and future therapies.
Mishra P; Jensen DM
Mt Sinai J Med; 2008 Aug; 75(4):405-14. PubMed ID: 18729159
[No Abstract] [Full Text] [Related]
11. [Sub-cutaneous injections].
Soins Gerontol; 2007; (65):45-6. PubMed ID: 17583291
[No Abstract] [Full Text] [Related]
12. [Management of chronic hepatitis in 2008].
Pol S; Marcellin P
Gastroenterol Clin Biol; 2008 Mar; 32(3 Pt 2):S71-3. PubMed ID: 18675183
[No Abstract] [Full Text] [Related]
13. Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis.
Tran HA; Malcolm Reeves GE; Gibson R; Attia JR
J Gastroenterol Hepatol; 2009 Jul; 24(7):1163-8. PubMed ID: 19682190
[TBL] [Abstract][Full Text] [Related]
14. Viral hepatitis: the clinical nurse specialist role.
Botterill G
Nurs Times; 2016 Apr 13-19; 112(15):15. PubMed ID: 27400621
[No Abstract] [Full Text] [Related]
15. Tongue hyperpigmentation during interferon-alpha and ribavirin therapy.
Aguayo-Leiva I; Pérez B; Salguero I; Jaén P
Eur J Dermatol; 2009; 19(3):291-2. PubMed ID: 19286489
[No Abstract] [Full Text] [Related]
16. Ribavirin trials and hantavirus--what we should not conclude.
Marcus KA; Johann-Liang R; Powers JH
Clin Infect Dis; 2005 May; 40(10):1550-1. PubMed ID: 15844085
[No Abstract] [Full Text] [Related]
17. FDA approves Hep C drugs.
AIDS Alert; 2004 Jun; 19(6):71. PubMed ID: 15272452
[No Abstract] [Full Text] [Related]
18. [Nursing care of the side effects of hepatitis treatments].
Muller N; de la Brière A
Soins; 2013 Nov; (780):38-40. PubMed ID: 24409615
[TBL] [Abstract][Full Text] [Related]
19. [Is hepatitis C important for drug addicts?].
Aavitsland P
Tidsskr Nor Laegeforen; 2009 Aug; 129(16):1623. PubMed ID: 19721475
[No Abstract] [Full Text] [Related]
20. The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: should we utilize more?
Aghemo A; Rumi MG; Prati GM; Colombo M
Hepatology; 2009 Feb; 49(2):702-3; author reply 703-4. PubMed ID: 19177585
[No Abstract] [Full Text] [Related]
[Next] [New Search]
